Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Convenes Panel To Review Drug-Associated Suicidality Study

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA joint committee meets July 10 to consider results of placebo-controlled trials of 11 drugs, including Lamictal, Carbatrol and Lyrica.

You may also be interested in...



Vivus’ Qnexa Combo For Obesity Needs FDA ‘Persuasion’ To Take First-Line In Diabetes

CEO hails positive Phase III data, but not all analysts are convinced.

Vivus’ Qnexa Combo For Obesity Needs FDA ‘Persuasion’ To Take First-Line In Diabetes

CEO hails positive Phase III data, but not all analysts are convinced.

FDA Panel To Review Ovation’s Sabril For Dual Epilepsy Indications

Vigabatrin set for review by Peripheral and Central Nervous System Drugs panel for seizures in adults and infantile spasms Aug. 6-7.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel